Is Microbot Medical Stock a Good Investment?
Microbot Medical Investment Advice | MBOT |
- Examine Microbot Medical's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Microbot Medical's leadership team and their track record. Good management can help Microbot Medical navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Microbot Medical's business and its evolving consumer preferences.
- Compare Microbot Medical's performance and market position to its competitors. Analyze how Microbot Medical is positioned in terms of product offerings, innovation, and market share.
- Check if Microbot Medical pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Microbot Medical's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Microbot Medical stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Microbot Medical is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Unstable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Microbot Medical Stock
Researching Microbot Medical's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was now reported as 0.38. The company recorded a loss per share of 0.79. Microbot Medical last dividend was issued on the 5th of September 2018. The entity had 1:15 split on the 5th of September 2018.
To determine if Microbot Medical is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Microbot Medical's research are outlined below:
| Microbot Medical generated a negative expected return over the last 90 days | |
| Microbot Medical has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (10.74 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Microbot Medical currently holds about 9.29 M in cash with (8.53 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Microbot Medical has a frail financial position based on the latest SEC disclosures |
Microbot Medical uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Microbot Medical. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Microbot Medical's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 15th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 29th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Microbot Medical's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Microbot Medical's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2018-03-22 | 2017-12-31 | -0.04 | -0.03 | 0.01 | 25 | ||
2024-11-12 | 2024-09-30 | -0.17 | -0.2 | -0.03 | 17 | ||
2020-05-15 | 2020-03-31 | -0.28 | -0.31 | -0.03 | 10 | ||
2023-11-13 | 2023-09-30 | -0.25 | -0.21 | 0.04 | 16 | ||
2019-08-14 | 2019-06-30 | -0.41 | -0.36 | 0.05 | 12 | ||
2023-08-14 | 2023-06-30 | -0.31 | -0.25 | 0.06 | 19 | ||
2019-05-15 | 2019-03-31 | -0.42 | -0.48 | -0.06 | 14 | ||
2020-11-16 | 2020-09-30 | -0.28 | -0.35 | -0.07 | 25 |
Know Microbot Medical's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Microbot Medical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Microbot Medical backward and forwards among themselves. Microbot Medical's institutional investor refers to the entity that pools money to purchase Microbot Medical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Securities, Llc | 2024-06-30 | 11.4 K | Susquehanna International Group, Llp | 2024-06-30 | 10.4 K | Stifel Financial Corp | 2024-06-30 | 10.3 K | Diamant Asset Management Inc | 2024-06-30 | 10 K | Tower Research Capital Llc | 2024-06-30 | 6.8 K | Beacon Capital Management, Llc | 2024-09-30 | 6 K | Bfsg, Llc | 2024-09-30 | 5.5 K | Group One Trading, Lp | 2024-06-30 | 4.6 K | Steward Partners Investment Advisory, Llc | 2024-06-30 | 2.3 K | Vanguard Group Inc | 2024-09-30 | 459.5 K | Blackrock Inc | 2024-06-30 | 137.4 K |
Microbot Medical's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.58 M.Market Cap |
|
Microbot Medical's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.29) | (1.23) | |
| Return On Capital Employed | (2.17) | (2.06) | |
| Return On Assets | (1.29) | (1.23) | |
| Return On Equity | (2.39) | (2.27) |
Determining Microbot Medical's profitability involves analyzing its financial statements and using various financial metrics to determine if Microbot Medical is a good buy. For example, gross profit margin measures Microbot Medical's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Microbot Medical's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Microbot Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Microbot Medical. Check Microbot Medical's Beneish M Score to see the likelihood of Microbot Medical's management manipulating its earnings.
Evaluate Microbot Medical's management efficiency
Microbot Medical has return on total asset (ROA) of (0.6488) % which means that it has lost $0.6488 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3446) %, meaning that it created substantial loss on money invested by shareholders. Microbot Medical's management efficiency ratios could be used to measure how well Microbot Medical manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -1.23 in 2024. Return On Capital Employed is likely to gain to -2.06 in 2024. Total Current Liabilities is likely to gain to about 4.8 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 7.9 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.44 | 0.42 | |
| Tangible Book Value Per Share | 0.44 | 0.42 | |
| Enterprise Value Over EBITDA | (1.36) | (1.43) | |
| Price Book Value Ratio | 3.72 | 3.90 | |
| Enterprise Value Multiple | (1.36) | (1.43) | |
| Price Fair Value | 3.72 | 3.90 | |
| Enterprise Value | 14.5 M | 28.5 M |
The management team at Microbot Medical has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Beta 1.628 |
Basic technical analysis of Microbot Stock
As of the 22nd of November, Microbot Medical secures the Mean Deviation of 2.19, standard deviation of 3.05, and Risk Adjusted Performance of (0.02). In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Microbot Medical, as well as the relationship between them.Microbot Medical's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Microbot Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Microbot Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Microbot Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yoseph Bornstein over three months ago Disposition of 45000 shares by Yoseph Bornstein of Microbot Medical at 1.0733 subject to Rule 16b-3 | ||
Yoseph Bornstein over three months ago Disposition of 32067 shares by Yoseph Bornstein of Microbot Medical at 1.03 subject to Rule 16b-3 | ||
Yoseph Bornstein over three months ago Disposition of 44159 shares by Yoseph Bornstein of Microbot Medical at 1.0372 subject to Rule 16b-3 | ||
Harel Gadot over six months ago Acquisition by Harel Gadot of 79567 shares of Microbot Medical at 1.25 subject to Rule 16b-3 | ||
Wenderow Tal Baruch over a year ago Acquisition by Wenderow Tal Baruch of 74218 shares of Microbot Medical subject to Rule 16b-3 | ||
Weissman Irving over a year ago Acquisition by Weissman Irving of 6068 shares of Microbot Medical subject to Rule 16b-3 |
Microbot Medical's Outstanding Corporate Bonds
Microbot Medical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Microbot Medical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Microbot bonds can be classified according to their maturity, which is the date when Microbot Medical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| US595017BA15 Corp BondUS595017BA15 | View |
Understand Microbot Medical's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Microbot Medical's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.19 | |||
| Coefficient Of Variation | (2,430) | |||
| Standard Deviation | 3.05 | |||
| Variance | 9.33 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 15.87 | |||
| Value At Risk | (4.95) | |||
| Potential Upside | 4.17 | |||
| Skewness | 0.8836 | |||
| Kurtosis | 2.17 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.20) | |||
| Mean Deviation | 2.19 | |||
| Coefficient Of Variation | (2,430) | |||
| Standard Deviation | 3.05 | |||
| Variance | 9.33 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.19) | |||
| Total Risk Alpha | (0.48) | |||
| Treynor Ratio | (0.21) | |||
| Maximum Drawdown | 15.87 | |||
| Value At Risk | (4.95) | |||
| Potential Upside | 4.17 | |||
| Skewness | 0.8836 | |||
| Kurtosis | 2.17 |
Consider Microbot Medical's intraday indicators
Microbot Medical intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Microbot Medical stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Microbot Medical time-series forecasting models is one of many Microbot Medical's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Microbot Medical's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Microbot Stock media impact
Far too much social signal, news, headlines, and media speculation about Microbot Medical that are available to investors today. That information is available publicly through Microbot media outlets and privately through word of mouth or via Microbot internal channels. However, regardless of the origin, that massive amount of Microbot data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Microbot Medical news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Microbot Medical relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Microbot Medical's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Microbot Medical alpha.
Microbot Medical Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Microbot Medical can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Microbot Medical Corporate Management
| Rachel Vaknin | Chief Officer | Profile | |
| Eyal MD | Chief Board | Profile | |
| Pr DSc | Scientific CoFounder | Profile | |
| Juan DiazCartelle | Chief Officer | Profile |
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.